A second EASL–Lancet Commission report, published today, evaluates the slow progress in addressing Europe's escalating liver disease crisis. The Commission's 2021 inaugural report had already documented an alarming increase in liver-related mortality across many European countries and proposed a detailed roadmap for change.
The new assessment warns that gaining consensus on what needs to be done remains relatively straightforward. The harder task, as one accompanying Comment article notes, involves overcoming "many vested interests, both professional and commercial." These entrenched forces continue to stall systemic improvements in prevention, diagnosis, and care.
The Commission did not provide new mortality statistics in this update but focused entirely on implementation gaps. It examined how previous recommendations have — or have not — been enacted by national health systems, policy makers, and industry stakeholders across the continent.
Without concrete data on adoption rates, the report serves more as a strategic nudge than a scorecard. Its value lies in naming the obstacles: fragmented healthcare policies, inconsistent funding, and resistance from commercial sectors tied to alcohol and ultra-processed foods that drive liver damage.
A counter-argument perspective notes that the Commission offers no fresh epidemiological evidence in this update. Critics may view the report as a reiteration of known problems without the measurable benchmarks needed to track real progress against the disease burden.